Page 2 - Mankind Pharma

Mankind Pharma inks pact with Innovent for immunotherapy drug in India

Drug used to treat non-small cell lung cancer, liver cancer, gastric cancer, esophageal cancer, endometrial cancer and Hodgkin's lymphoma will be priced competitively

Mankind Pharma inks pact with Innovent for immunotherapy drug in India

Mankind Pharma Ltd and Innovent Biologics on Thursday announced a partnership to exclusively license and commercialise innovative immunotherapy drug Sintilimab, used in the treatment of cancer, in the Indian market. This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region, the companies said in a joint statement. Marketed as TYVYT (sintilimab injection) in China, Sintilimab is co-developed by Innovent and Eli Lilly. "Sintilimab is not approved in India. Early next year, we will be filing for its regulatory approval in India and complete all mandatory regulatory processes, including the conducting of a phase 3 clinical trial by Mankind Pharma for its successful approval in India once we receive the permission from the regulator to conduct such clinical trials," a Mankind Pharma spokesperson said. Under the agreement with Innovent, Mankind Pharma will have exclusive rights to ..

Mankind Pharma dips 5% on profit booking after listing of QIP shares

Mankind Pharma's shares hit a record high of Rs 3,050 on Monday and rallied 13 per cent in past four trading days

Mankind Pharma rises on launching QIP at floor price of Rs 2,616.55

The company launched its qualified institutional placement (QIP) at a floor price of Rs 2,616.55 per share aiming to raise up to Rs 3,000 crore

Mankind Pharma pledges 39.68% in Bharat Serums for Rs 5K crore NCDs

The capital raised through this pledge is expected to support Mankind Pharma's strategic initiatives and growth plans

Mankind Pharma up 6% as PAT rises 29%, margins up 220 bps in Q2FY25

Mankind Pharma declared its September quarter numbers on Tuesday after market hours

Mankind Pharma Q2 results: PAT rises 29% to Rs 659 crore, revenue up 14%

Mankind's revenue from operations rose to Rs 3,077 crore in Q2 FY25, a 13.6 per cent Y-o-Y rise from Rs 2,708 crore reported in Q2 FY24

Mankind Pharma Q2 results: Net profit rises to Rs 653 cr on higher demand

The company, which also makes Manforce condoms and Prega News pregnancy kits, said its consolidated net profit rose to RS 653 crore for the quarter ended Sep 30, a 30% climb from last year

RVNL, Polycab, CG Power: Technical view on stocks that may turn large-caps

Nuvama Alternative & Quantitative Research in its early predictions on AMFI semi-annual categorization expects RVNL, Polycab India and 5 other stocks to be upgraded to large-caps.

Mankind completes Rs 13,768 cr acquisition of Bharat Serums and Vaccines

The announcement was made after market hours. On Wednesday, Mankind Pharma's shares closed at Rs 2,529.80 apiece, down 1.46 per cent on the Bombay Stock Exchange (BSE)

Mankind Pharma, Bajaj Housing, Ola Electric, 40 others to exit IPO lock-in

Here is the complete list of stocks exiting their IPO lock-in period between October 8, 2024, and December 31, 2024

Stocks To Watch: SBI, Mankind, Adani Enterprises, Dr. Reddy's, Zydus Life

Stocks to watch: SBI plans to open 600 new branches this fiscal year to expand its reach in emerging residential areas, said its chairman and managing director CS Setty.

CCI approves Mankind Pharma's purchase of Bharat Serums for $1.6 bn

Mankind Pharma, which has brands including Manforce condoms and Prega News pregnancy tests, signed an agreement to acquire Bharat Serums

Mankind Pharma board approves fundraising plan of up to Rs 10,000 cr

Mankind Pharma on Monday said it will raise up to Rs 10,000 crore via issuance of non-convertible debentures and commercial papers. The company said its board has approved to raise up to Rs 5,000 crore via non-convertible debentures in 3-4 distinct series with maturities of up to 48 months. The board's fundraising committee also approved to raise up to Rs 5,000 crore via listed and rated commercial papers, having face value as may be decided in accordance with applicable law, in one or more tranches or series, the drug maker said in a regulatory filing. The company, however, did not disclose how it aims to utilise the raised capital. In July this year, Mankind had announced the acquisition of Bharat Serums and Vaccines from Advent International for around Rs 13,630 crore. The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and consumer healthcare products. Shares of the company on Monday ended 2.68 per cent down at Rs .

Mankind Pharma up 4% as board approves raising Rs 10,000-cr via NCDs, CPs

Mankind Pharma approved raising Rs 10,000 crore via the issuance of Non-Convertible Debentures (NCD) and Commercial Papers (CP)

Mankind Pharma to raise funds up to Rs 10k crore via debt instruments

The board announced the issuance of corporate guarantees for four of its subsidiaries, namely Mankind Agritech, Appian Properties, Copmed Pharmaceuticals, and Lifestar Pharma.

Mankind up 7% ahead of board meet for fund raising; m-cap tops Rs 1 trn

The board is to consider and approve the raising of funds by way of issue of non-convertible debentures, commercial papers, other debt securities or any other security or any combination thereof.

Mankind Pharma shares gain after OTC biz transfer to subsidiary; details

Mankind Pharma share price surged after the company on Tuesday completed a business transfer agreement (BTA) to shift its over-the-counter (OTC) business to its wholly owned subsidiary

Mankind up 3% after reports say co looking to raise Rs 9k cr for BSV deal

Mankind Pharma is likely to raise Rs 9,000 crore through NCDs to acquire Bharat Serums and Vaccines

Mankind Pharma plans Rs 9,000 crore raise for Bharat Serums acquisition

The move will position Mankind as a leader in the gynaecology-fertility segment, with an anticipated market share of around 20%, surpassing Emcure